Breast Cancer Clinical Trial
Official title:
Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable
adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred
to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128)
targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and
potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents
cellular proliferation.
The mTOR complex (mTORC) is an important therapeutic target that is generally stable (i.e.,
low tendency to mutate) and is a key intracellular point of convergence for a number of
cellular signaling pathways. Inhibiting mTOR may inhibit abnormal cell proliferation, tumor
angiogenesis, and abnormal cellular metabolism, thus providing the rationale for mTOR
inhibitors as potential agents in the treatment of a number of indications including solid
tumor and hematological malignancies, as either monotherapy or in combination with other
chemotherapeutic agents. Like rapamycin, several newly approved rapalogs (temsirolimus and
everolimus) are specific and allosteric inhibitors of mTORC1, and only partially inhibit
mTORC1 signaling pathways. They do not directly inhibit mTORC2, which has shown to be an
emerging target in cancer research. TAK-228 was developed to address the incomplete
inhibition of the mTOR pathway by rapalogs.
Eligible subjects will have a research biopsy and baseline blood and urine studies done
within two weeks prior to start of study treatment. Subjects will then be treated with
TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.
The subject will then be treated with the combination of TAK-228 and letrozole for an
additional 110 days, before undergoing resection of the primary tumor. Subjects will be
treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose
deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more
of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded
to include six to ten subjects.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |